Aurigene Discovery & CDMO is a wholly owned subsidiary of Dr. Reddy’s Laboratories. It was created in 2020 by merging all service businesses within Dr. Reddy’s to build a strong customer-centric organization. Thus, Aurigene is a young and nimble company with more than two decades of experience.
Aurigene partners with global pharmaceutical and biotech companies to advance their molecules from laboratory to market. Aurigene offers integrated API, intermediate, and formulation services that span key starting materials, advanced intermediates, and APIs to finished products such as oral solids, sterile products, nasal solutions, and more. Aurigene lives by its purpose to accelerate access to affordable and innovative medicines because Good Health Can’t Wait.
Aurigene’ s focus on scientific expertise, technology, innovation, and problem-solving—along with strong fundamentals in sustainability, compliance, and IP security—has made it a preferred partner for many large pharma and biotech companies. Aurigene believes in fostering and nurturing long-term partnerships through work built on speed, adaptability, clarity of communication, and collaboration.
免责声明
本網站上的任何信息，包括對任何產品或服務的任何提及，均不構成銷售要約或被解釋為代表銷售要約。受有效專利保護的產品不得提供或供應用於商業用途。但是，在某些情況下，雷迪博士可自行決定並根據當地法律要求，在存在此類監管豁免的任何地方，提供此類產品的研究數量，以根據《印度專利法》第 107A 條（Bolar 豁免）進行監管提交。購買者應對其各自市場的產品或服務（包括專利情況）進行獨立評估，並對所有與專利相關的責任負責。 Dr. Reddy's 不承擔任何明示或暗示的保證，包括但不限於適銷性、適用於特定用途和非侵權的保證。